Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 6/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12877871 | 0.88 | PDK2 (0.44) | TSHRALOX15ATMGPR119PDK2 | |
| SCHEMBL29505978 | 0.87 | PDK2 (0.43) | TSHRALOX15ATMGPR119PDK2 | |
| SCHEMBL31158306 | 0.87 | ADRA1D (0.45) | ADRA1DADRA1AADRA1BTSHRALOX15 | |
| SCHEMBL29446735 | 0.87 | GPR119 (0.44) | TSHRALOX15ATMGPR119PDK2 | |
| SCHEMBL1513325 | 0.87 | ADRA1D (0.45) | ADRA1DADRA1AADRA1BTSHRALOX15 | |
| SCHEMBL4362609 | 0.87 | GPR119 (0.44) | TSHRALOX15ATMGPR119PDK2 | |
| SCHEMBL7704701 | 0.87 | GPR119 (0.47) | TSHRALOX15ATMGPR119PDK2 | |
| SCHEMBL21855700 | 0.87 | PDK2 (0.43) | TSHRALOX15ATMGPR119PDK2 | |
| SCHEMBL3254660 | 0.86 | ADRA1D (0.47) | ADRA1DADRA1AADRA1BAPPTSHR | |
| SCHEMBL30074774 | 0.86 | ADRA1D (0.47) | ADRA1DADRA1AADRA1BAPPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME (US) | 2014-11-13 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| US-6358959-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| US-6319932-B1 | USEFUL FOR TREATING BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-11-20 | — | — | US | disclosed |
| US-6274583-B1 | Alpha 1a adrenergic receptor antagonists | MERCK & CO., INC. | 2001-08-14 | — | — | US | disclosed |
| US-6228870-B1 | BENIGN PROSTATIC HYPERPLASIA; REDUCTION OF HYPOTENSION SIDE EFFECT | MERCK & CO., INC. | 2001-05-08 | — | — | US | disclosed |
| WO-2000043374-A1 | POLYAZANAPHTHALENONE DERIVATIVES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000027827-A1 | OXAZOLIDINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000027817-A1 | OXAZOLIDINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| US-5977115-A | Alpha 1a adrenergic receptor antagonists | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5922722-A | PIPERIDINE OR PIPERAZINE DERIVATIVES TO TREAT BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0833637-A4 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | MERCK & CO INC (US) | 1998-07-08 | — | — | EP | disclosed |
| EP-0833637-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5661163-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1997-08-26 | — | — | US | disclosed |
| WO-1996040136-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336222-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF | TP53, TP53BP1, MDM2 | ADRA1D 4609/4885ADRA1A 4610/4885ADRA1B 4678/4885 |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | TP53, MDM2, TP53BP1 | ADRA1D 4738/4885ADRA1A 4721/4885ADRA1B 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.